

- In a manner not clear to us, a principle investigator of the UGDP was engaged by the FDA and appears from documents available to us to have participated in the preparation of FDA material relating to the legal aspects of this controversy.

- When challenges to the validity of the study could not be silenced, the NIH arranged for Dr. Thomas C. Chalmers to have the Biometric Society undertake an analysis primarily of the statistical aspects of the study, despite the fact that many if not most of the central criticism was clinical in nature. The same Dr. Chalmers now appears as the author of an editorial in the J. A. M. A. in which he modestly omits his personal role as a government official in arranging for the Biometric Society study as he proceeds to hail its findings, to support it with selections of references relating to experimental and human studies, while omitting all controverting reports in the literature.

I do not know what this is called in science. In politics it has been called a "cover-up". There is need for further inquiry into the whole area of the treatment of diabetes and also the role of government agencies and individuals in the UGDP affair.